Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?

140
11
Favorite

Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?

InvestorPlace2022-08-03

Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

140

Report

Comment（11）

HappyChoo
·2022-08-03
Read
Reply
Like
Report
Shishir
·2022-08-03
Ok
Reply
2
Report
Mich77
·2022-08-03
read
Reply
3
Report
ccwee
·2022-08-03
read
Reply
3
Report
KenixBoon88
·2022-08-03
Noted with thanks
Reply
4
Report
Billionaire Pinky Pig Monkey
·2022-08-03
Ok
Reply
4
Report
ALi_BaBa
·2022-08-03
Like
Reply
5
Report
DarrenTayCW
·2022-08-03
ok
Reply
3
Report
pkcruns
·2022-08-03
ok
Reply
4
Report
Singman
·2022-08-03
Like
Reply
5
Report
potato112
·2022-08-03
Like pls. Tq!
Reply
10
Report
Fold Replies
- potato112:
  comment back haha
  2022-09-09
  Reply
  Report
- JeremyKok:
  hi, please like and comment back. thank you.
  2022-08-05
  Reply
  Report
- Pepermintpat:
  LIke
  2022-08-03
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2256409604?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-08-03 09:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2256409604","market":"us","top_or_hot":-1,"title":"Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?","media":"InvestorPlace","content":"<div>\n<p>Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough...</p>\n\n<a href=\"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/\">Source Link</a>\n\n</div>\n","source":"investorplace","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Cannabis Stocks TLRY, CGC, CRON Up Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-03 09:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough...</p>\n\n<a href=\"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRON","symbol_name":"Cronos Group Inc.","start_time":0,"source_url":"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/","article_id":"2256409604","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2256409604","pubTimestamp":1659489465,"columns":[],"sourceInfo":{"source_id":"investorplace","name":"InvestorPlace"},"weMediaInfo":null,"summary":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRON":"Cronos Group Inc.","BK4557":"大麻股","TLRY":"Tilray Inc.","BK4547":"WSB热门概念","CGC":"Canopy Growth Corporation","BK4007":"制药"},"translate_title":"为什么今天大麻库存TLRY，CGC，CRON上升？","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGC":1,"CRON":1,"TLRY":1},"content_text":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.Growing international legalization momentum also fundamentally support cannabis stocks.Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players Tilray (NASDAQ:TLRY), Canopy Growth (NASDAQ:CGC) and Cronos (NASDAQ:CRON) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.On the international front, cannabis stocks may be responding to a Forbes article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.Interestingly, Tilray tweeted a link to the Forbes article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.Cannabis Stocks Still Have a Challenging Road AheadJefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.Why It MattersAlthough beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9906825421,"gmtCreate":1659520437266,"gmtModify":1705981215440,"author":{"id":"4092525468598030","authorId":"4092525468598030","name":"HappyChoo","avatar":"https://static.tigerbbs.com/cde9e6e4075951008604ea783f99efed","vip":1,"crmLevel":4,"crmLevelSwitch":1,"idStr":"4092525468598030","authorIdStr":"4092525468598030"},"htmlText":"Read","listText":"Read","text":"Read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9906825421","repostId":2256409604,"repostType":4,"repost":{"id":"2256409604","kind":"highlight","pubTimestamp":1659489465,"share":"https://ttm.financial/m/news/2256409604?lang=&edition=fundamental","pubTime":"2022-08-03 09:17","market":"us","language":"en","title":"Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2256409604","media":"InvestorPlace","summary":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON","content":"<html><head></head><body><ul><li>Cannabis stocks are on the move today, including <b>Tilray</b> (<b><u>TLRY</u></b>), <b>Canopy Growth</b> (<b><u>CGC</u></b>) and <b>Cronos</b> (<b><u>CRON</u></b>), among others.</li><li>Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.</li><li>Growing international legalization momentum also fundamentally support cannabis stocks.<img src=\"https://static.tigerbbs.com/54622a5e690d654992a438adc0feb663\" tg-width=\"768\" tg-height=\"432\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></li></ul><p>Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players <b>Tilray</b> (NASDAQ:<b><u>TLRY</u></b>), <b>Canopy Growth</b> (NASDAQ:<b><u>CGC</u></b>) and <b>Cronos</b> (NASDAQ:<b><u>CRON</u></b>) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.</p><p>On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.</p><p>In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.</p><p>On the international front, cannabis stocks may be responding to a <i>Forbes</i> article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.</p><p>Interestingly, Tilray tweeted a link to the <i>Forbes</i> article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.</p><h2>Cannabis Stocks Still Have a Challenging Road Ahead</h2><p>Jefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.</p><p>This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.</p><p>A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.</p><p>Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.</p><p>Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”</p><p>In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.</p><h2>Why It Matters</h2><p>Although beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Cannabis Stocks TLRY, CGC, CRON Up Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-03 09:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough...</p>\n\n<a href=\"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","CGC":"Canopy Growth Corporation","BK4557":"大麻股","TLRY":"Tilray Inc.","BK4547":"WSB热门概念","CRON":"Cronos Group Inc."},"source_url":"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2256409604","content_text":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.Growing international legalization momentum also fundamentally support cannabis stocks.Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players Tilray (NASDAQ:TLRY), Canopy Growth (NASDAQ:CGC) and Cronos (NASDAQ:CRON) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.On the international front, cannabis stocks may be responding to a Forbes article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.Interestingly, Tilray tweeted a link to the Forbes article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.Cannabis Stocks Still Have a Challenging Road AheadJefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.Why It MattersAlthough beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9906170288,"gmtCreate":1659504211147,"gmtModify":1705981088805,"author":{"id":"3577771722524346","authorId":"3577771722524346","name":"Shishir","avatar":"https://static.tigerbbs.com/5bbb5ffb9814e2b46f518ffcbf85ff64","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":3,"crmLevelSwitch":1,"idStr":"3577771722524346","authorIdStr":"3577771722524346"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9906170288","repostId":2256409604,"repostType":4,"repost":{"id":"2256409604","kind":"highlight","pubTimestamp":1659489465,"share":"https://ttm.financial/m/news/2256409604?lang=&edition=fundamental","pubTime":"2022-08-03 09:17","market":"us","language":"en","title":"Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2256409604","media":"InvestorPlace","summary":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON","content":"<html><head></head><body><ul><li>Cannabis stocks are on the move today, including <b>Tilray</b> (<b><u>TLRY</u></b>), <b>Canopy Growth</b> (<b><u>CGC</u></b>) and <b>Cronos</b> (<b><u>CRON</u></b>), among others.</li><li>Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.</li><li>Growing international legalization momentum also fundamentally support cannabis stocks.<img src=\"https://static.tigerbbs.com/54622a5e690d654992a438adc0feb663\" tg-width=\"768\" tg-height=\"432\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></li></ul><p>Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players <b>Tilray</b> (NASDAQ:<b><u>TLRY</u></b>), <b>Canopy Growth</b> (NASDAQ:<b><u>CGC</u></b>) and <b>Cronos</b> (NASDAQ:<b><u>CRON</u></b>) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.</p><p>On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.</p><p>In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.</p><p>On the international front, cannabis stocks may be responding to a <i>Forbes</i> article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.</p><p>Interestingly, Tilray tweeted a link to the <i>Forbes</i> article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.</p><h2>Cannabis Stocks Still Have a Challenging Road Ahead</h2><p>Jefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.</p><p>This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.</p><p>A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.</p><p>Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.</p><p>Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”</p><p>In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.</p><h2>Why It Matters</h2><p>Although beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Cannabis Stocks TLRY, CGC, CRON Up Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-03 09:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough...</p>\n\n<a href=\"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","CGC":"Canopy Growth Corporation","BK4557":"大麻股","TLRY":"Tilray Inc.","BK4547":"WSB热门概念","CRON":"Cronos Group Inc."},"source_url":"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2256409604","content_text":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.Growing international legalization momentum also fundamentally support cannabis stocks.Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players Tilray (NASDAQ:TLRY), Canopy Growth (NASDAQ:CGC) and Cronos (NASDAQ:CRON) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.On the international front, cannabis stocks may be responding to a Forbes article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.Interestingly, Tilray tweeted a link to the Forbes article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.Cannabis Stocks Still Have a Challenging Road AheadJefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.Why It MattersAlthough beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9906182588,"gmtCreate":1659496434146,"gmtModify":1705981016729,"author":{"id":"3581849551321020","authorId":"3581849551321020","name":"Mich77","avatar":"https://static.tigerbbs.com/e68e0beedd6e067e59c605653c639699","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581849551321020","authorIdStr":"3581849551321020"},"htmlText":"read","listText":"read","text":"read","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9906182588","repostId":2256409604,"repostType":4,"repost":{"id":"2256409604","kind":"highlight","pubTimestamp":1659489465,"share":"https://ttm.financial/m/news/2256409604?lang=&edition=fundamental","pubTime":"2022-08-03 09:17","market":"us","language":"en","title":"Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2256409604","media":"InvestorPlace","summary":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON","content":"<html><head></head><body><ul><li>Cannabis stocks are on the move today, including <b>Tilray</b> (<b><u>TLRY</u></b>), <b>Canopy Growth</b> (<b><u>CGC</u></b>) and <b>Cronos</b> (<b><u>CRON</u></b>), among others.</li><li>Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.</li><li>Growing international legalization momentum also fundamentally support cannabis stocks.<img src=\"https://static.tigerbbs.com/54622a5e690d654992a438adc0feb663\" tg-width=\"768\" tg-height=\"432\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></li></ul><p>Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players <b>Tilray</b> (NASDAQ:<b><u>TLRY</u></b>), <b>Canopy Growth</b> (NASDAQ:<b><u>CGC</u></b>) and <b>Cronos</b> (NASDAQ:<b><u>CRON</u></b>) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.</p><p>On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.</p><p>In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.</p><p>On the international front, cannabis stocks may be responding to a <i>Forbes</i> article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.</p><p>Interestingly, Tilray tweeted a link to the <i>Forbes</i> article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.</p><h2>Cannabis Stocks Still Have a Challenging Road Ahead</h2><p>Jefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.</p><p>This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.</p><p>A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.</p><p>Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.</p><p>Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”</p><p>In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.</p><h2>Why It Matters</h2><p>Although beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Cannabis Stocks TLRY, CGC, CRON Up Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-03 09:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough...</p>\n\n<a href=\"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","CGC":"Canopy Growth Corporation","BK4557":"大麻股","TLRY":"Tilray Inc.","BK4547":"WSB热门概念","CRON":"Cronos Group Inc."},"source_url":"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2256409604","content_text":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.Growing international legalization momentum also fundamentally support cannabis stocks.Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players Tilray (NASDAQ:TLRY), Canopy Growth (NASDAQ:CGC) and Cronos (NASDAQ:CRON) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.On the international front, cannabis stocks may be responding to a Forbes article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.Interestingly, Tilray tweeted a link to the Forbes article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.Cannabis Stocks Still Have a Challenging Road AheadJefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.Why It MattersAlthough beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9906188989,"gmtCreate":1659496067746,"gmtModify":1705981012470,"author":{"id":"3581829959470650","authorId":"3581829959470650","name":"ccwee","avatar":"https://static.tigerbbs.com/652d99331e3c23c682d7e58cfc9f6544","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581829959470650","authorIdStr":"3581829959470650"},"htmlText":"read","listText":"read","text":"read","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9906188989","repostId":2256409604,"repostType":4,"repost":{"id":"2256409604","kind":"highlight","pubTimestamp":1659489465,"share":"https://ttm.financial/m/news/2256409604?lang=&edition=fundamental","pubTime":"2022-08-03 09:17","market":"us","language":"en","title":"Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2256409604","media":"InvestorPlace","summary":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON","content":"<html><head></head><body><ul><li>Cannabis stocks are on the move today, including <b>Tilray</b> (<b><u>TLRY</u></b>), <b>Canopy Growth</b> (<b><u>CGC</u></b>) and <b>Cronos</b> (<b><u>CRON</u></b>), among others.</li><li>Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.</li><li>Growing international legalization momentum also fundamentally support cannabis stocks.<img src=\"https://static.tigerbbs.com/54622a5e690d654992a438adc0feb663\" tg-width=\"768\" tg-height=\"432\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></li></ul><p>Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players <b>Tilray</b> (NASDAQ:<b><u>TLRY</u></b>), <b>Canopy Growth</b> (NASDAQ:<b><u>CGC</u></b>) and <b>Cronos</b> (NASDAQ:<b><u>CRON</u></b>) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.</p><p>On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.</p><p>In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.</p><p>On the international front, cannabis stocks may be responding to a <i>Forbes</i> article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.</p><p>Interestingly, Tilray tweeted a link to the <i>Forbes</i> article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.</p><h2>Cannabis Stocks Still Have a Challenging Road Ahead</h2><p>Jefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.</p><p>This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.</p><p>A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.</p><p>Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.</p><p>Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”</p><p>In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.</p><h2>Why It Matters</h2><p>Although beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Cannabis Stocks TLRY, CGC, CRON Up Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-03 09:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough...</p>\n\n<a href=\"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","CGC":"Canopy Growth Corporation","BK4557":"大麻股","TLRY":"Tilray Inc.","BK4547":"WSB热门概念","CRON":"Cronos Group Inc."},"source_url":"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2256409604","content_text":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.Growing international legalization momentum also fundamentally support cannabis stocks.Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players Tilray (NASDAQ:TLRY), Canopy Growth (NASDAQ:CGC) and Cronos (NASDAQ:CRON) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.On the international front, cannabis stocks may be responding to a Forbes article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.Interestingly, Tilray tweeted a link to the Forbes article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.Cannabis Stocks Still Have a Challenging Road AheadJefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.Why It MattersAlthough beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9906137098,"gmtCreate":1659494117217,"gmtModify":1705980988201,"author":{"id":"4087201086871900","authorId":"4087201086871900","name":"KenixBoon88","avatar":"https://static.tigerbbs.com/9ddde31e83f2e33f47a5875ef7251f84","vip":1,"crmLevel":6,"crmLevelSwitch":1,"idStr":"4087201086871900","authorIdStr":"4087201086871900"},"htmlText":"Noted with thanks&nbsp;","listText":"Noted with thanks&nbsp;","text":"Noted with thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9906137098","repostId":2256409604,"repostType":4,"repost":{"id":"2256409604","kind":"highlight","pubTimestamp":1659489465,"share":"https://ttm.financial/m/news/2256409604?lang=&edition=fundamental","pubTime":"2022-08-03 09:17","market":"us","language":"en","title":"Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2256409604","media":"InvestorPlace","summary":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON","content":"<html><head></head><body><ul><li>Cannabis stocks are on the move today, including <b>Tilray</b> (<b><u>TLRY</u></b>), <b>Canopy Growth</b> (<b><u>CGC</u></b>) and <b>Cronos</b> (<b><u>CRON</u></b>), among others.</li><li>Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.</li><li>Growing international legalization momentum also fundamentally support cannabis stocks.<img src=\"https://static.tigerbbs.com/54622a5e690d654992a438adc0feb663\" tg-width=\"768\" tg-height=\"432\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></li></ul><p>Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players <b>Tilray</b> (NASDAQ:<b><u>TLRY</u></b>), <b>Canopy Growth</b> (NASDAQ:<b><u>CGC</u></b>) and <b>Cronos</b> (NASDAQ:<b><u>CRON</u></b>) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.</p><p>On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.</p><p>In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.</p><p>On the international front, cannabis stocks may be responding to a <i>Forbes</i> article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.</p><p>Interestingly, Tilray tweeted a link to the <i>Forbes</i> article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.</p><h2>Cannabis Stocks Still Have a Challenging Road Ahead</h2><p>Jefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.</p><p>This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.</p><p>A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.</p><p>Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.</p><p>Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”</p><p>In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.</p><h2>Why It Matters</h2><p>Although beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Cannabis Stocks TLRY, CGC, CRON Up Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-03 09:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough...</p>\n\n<a href=\"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","CGC":"Canopy Growth Corporation","BK4557":"大麻股","TLRY":"Tilray Inc.","BK4547":"WSB热门概念","CRON":"Cronos Group Inc."},"source_url":"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2256409604","content_text":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.Growing international legalization momentum also fundamentally support cannabis stocks.Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players Tilray (NASDAQ:TLRY), Canopy Growth (NASDAQ:CGC) and Cronos (NASDAQ:CRON) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.On the international front, cannabis stocks may be responding to a Forbes article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.Interestingly, Tilray tweeted a link to the Forbes article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.Cannabis Stocks Still Have a Challenging Road AheadJefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.Why It MattersAlthough beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9906130602,"gmtCreate":1659493150208,"gmtModify":1705980974274,"author":{"id":"3568071651427696","authorId":"3568071651427696","name":"Billionaire Pinky Pig Monkey","avatar":"https://static.tigerbbs.com/3402225c0172781df7553e20722ebad7","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3568071651427696","authorIdStr":"3568071651427696"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9906130602","repostId":2256409604,"repostType":4,"repost":{"id":"2256409604","kind":"highlight","pubTimestamp":1659489465,"share":"https://ttm.financial/m/news/2256409604?lang=&edition=fundamental","pubTime":"2022-08-03 09:17","market":"us","language":"en","title":"Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2256409604","media":"InvestorPlace","summary":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON","content":"<html><head></head><body><ul><li>Cannabis stocks are on the move today, including <b>Tilray</b> (<b><u>TLRY</u></b>), <b>Canopy Growth</b> (<b><u>CGC</u></b>) and <b>Cronos</b> (<b><u>CRON</u></b>), among others.</li><li>Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.</li><li>Growing international legalization momentum also fundamentally support cannabis stocks.<img src=\"https://static.tigerbbs.com/54622a5e690d654992a438adc0feb663\" tg-width=\"768\" tg-height=\"432\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></li></ul><p>Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players <b>Tilray</b> (NASDAQ:<b><u>TLRY</u></b>), <b>Canopy Growth</b> (NASDAQ:<b><u>CGC</u></b>) and <b>Cronos</b> (NASDAQ:<b><u>CRON</u></b>) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.</p><p>On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.</p><p>In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.</p><p>On the international front, cannabis stocks may be responding to a <i>Forbes</i> article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.</p><p>Interestingly, Tilray tweeted a link to the <i>Forbes</i> article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.</p><h2>Cannabis Stocks Still Have a Challenging Road Ahead</h2><p>Jefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.</p><p>This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.</p><p>A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.</p><p>Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.</p><p>Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”</p><p>In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.</p><h2>Why It Matters</h2><p>Although beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Cannabis Stocks TLRY, CGC, CRON Up Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-03 09:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough...</p>\n\n<a href=\"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","CGC":"Canopy Growth Corporation","BK4557":"大麻股","TLRY":"Tilray Inc.","BK4547":"WSB热门概念","CRON":"Cronos Group Inc."},"source_url":"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2256409604","content_text":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.Growing international legalization momentum also fundamentally support cannabis stocks.Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players Tilray (NASDAQ:TLRY), Canopy Growth (NASDAQ:CGC) and Cronos (NASDAQ:CRON) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.On the international front, cannabis stocks may be responding to a Forbes article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.Interestingly, Tilray tweeted a link to the Forbes article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.Cannabis Stocks Still Have a Challenging Road AheadJefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.Why It MattersAlthough beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9906196574,"gmtCreate":1659492734500,"gmtModify":1705980966340,"author":{"id":"3564105303063302","authorId":"3564105303063302","name":"ALi_BaBa","avatar":"https://static.tigerbbs.com/d89722c800111c9c885624fce940701f","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3564105303063302","authorIdStr":"3564105303063302"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9906196574","repostId":2256409604,"repostType":4,"repost":{"id":"2256409604","kind":"highlight","pubTimestamp":1659489465,"share":"https://ttm.financial/m/news/2256409604?lang=&edition=fundamental","pubTime":"2022-08-03 09:17","market":"us","language":"en","title":"Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2256409604","media":"InvestorPlace","summary":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON","content":"<html><head></head><body><ul><li>Cannabis stocks are on the move today, including <b>Tilray</b> (<b><u>TLRY</u></b>), <b>Canopy Growth</b> (<b><u>CGC</u></b>) and <b>Cronos</b> (<b><u>CRON</u></b>), among others.</li><li>Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.</li><li>Growing international legalization momentum also fundamentally support cannabis stocks.<img src=\"https://static.tigerbbs.com/54622a5e690d654992a438adc0feb663\" tg-width=\"768\" tg-height=\"432\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></li></ul><p>Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players <b>Tilray</b> (NASDAQ:<b><u>TLRY</u></b>), <b>Canopy Growth</b> (NASDAQ:<b><u>CGC</u></b>) and <b>Cronos</b> (NASDAQ:<b><u>CRON</u></b>) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.</p><p>On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.</p><p>In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.</p><p>On the international front, cannabis stocks may be responding to a <i>Forbes</i> article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.</p><p>Interestingly, Tilray tweeted a link to the <i>Forbes</i> article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.</p><h2>Cannabis Stocks Still Have a Challenging Road Ahead</h2><p>Jefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.</p><p>This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.</p><p>A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.</p><p>Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.</p><p>Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”</p><p>In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.</p><h2>Why It Matters</h2><p>Although beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Cannabis Stocks TLRY, CGC, CRON Up Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-03 09:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough...</p>\n\n<a href=\"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","CGC":"Canopy Growth Corporation","BK4557":"大麻股","TLRY":"Tilray Inc.","BK4547":"WSB热门概念","CRON":"Cronos Group Inc."},"source_url":"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2256409604","content_text":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.Growing international legalization momentum also fundamentally support cannabis stocks.Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players Tilray (NASDAQ:TLRY), Canopy Growth (NASDAQ:CGC) and Cronos (NASDAQ:CRON) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.On the international front, cannabis stocks may be responding to a Forbes article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.Interestingly, Tilray tweeted a link to the Forbes article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.Cannabis Stocks Still Have a Challenging Road AheadJefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.Why It MattersAlthough beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9906102093,"gmtCreate":1659491873714,"gmtModify":1705980950463,"author":{"id":"4095157923406380","authorId":"4095157923406380","name":"DarrenTayCW","avatar":"https://community-static.tradeup.com/news/fd3e65152635880712a6be051f621efa","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4095157923406380","authorIdStr":"4095157923406380"},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9906102093","repostId":2256409604,"repostType":4,"repost":{"id":"2256409604","kind":"highlight","pubTimestamp":1659489465,"share":"https://ttm.financial/m/news/2256409604?lang=&edition=fundamental","pubTime":"2022-08-03 09:17","market":"us","language":"en","title":"Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2256409604","media":"InvestorPlace","summary":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON","content":"<html><head></head><body><ul><li>Cannabis stocks are on the move today, including <b>Tilray</b> (<b><u>TLRY</u></b>), <b>Canopy Growth</b> (<b><u>CGC</u></b>) and <b>Cronos</b> (<b><u>CRON</u></b>), among others.</li><li>Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.</li><li>Growing international legalization momentum also fundamentally support cannabis stocks.<img src=\"https://static.tigerbbs.com/54622a5e690d654992a438adc0feb663\" tg-width=\"768\" tg-height=\"432\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></li></ul><p>Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players <b>Tilray</b> (NASDAQ:<b><u>TLRY</u></b>), <b>Canopy Growth</b> (NASDAQ:<b><u>CGC</u></b>) and <b>Cronos</b> (NASDAQ:<b><u>CRON</u></b>) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.</p><p>On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.</p><p>In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.</p><p>On the international front, cannabis stocks may be responding to a <i>Forbes</i> article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.</p><p>Interestingly, Tilray tweeted a link to the <i>Forbes</i> article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.</p><h2>Cannabis Stocks Still Have a Challenging Road Ahead</h2><p>Jefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.</p><p>This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.</p><p>A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.</p><p>Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.</p><p>Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”</p><p>In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.</p><h2>Why It Matters</h2><p>Although beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Cannabis Stocks TLRY, CGC, CRON Up Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-03 09:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough...</p>\n\n<a href=\"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","CGC":"Canopy Growth Corporation","BK4557":"大麻股","TLRY":"Tilray Inc.","BK4547":"WSB热门概念","CRON":"Cronos Group Inc."},"source_url":"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2256409604","content_text":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.Growing international legalization momentum also fundamentally support cannabis stocks.Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players Tilray (NASDAQ:TLRY), Canopy Growth (NASDAQ:CGC) and Cronos (NASDAQ:CRON) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.On the international front, cannabis stocks may be responding to a Forbes article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.Interestingly, Tilray tweeted a link to the Forbes article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.Cannabis Stocks Still Have a Challenging Road AheadJefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.Why It MattersAlthough beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9906376422,"gmtCreate":1659490986269,"gmtModify":1705980933755,"author":{"id":"3568929142732138","authorId":"3568929142732138","name":"pkcruns","avatar":"https://static.tigerbbs.com/7e60c6b4c459f970f04a7674c89a4e2c","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3568929142732138","authorIdStr":"3568929142732138"},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9906376422","repostId":2256409604,"repostType":4,"repost":{"id":"2256409604","kind":"highlight","pubTimestamp":1659489465,"share":"https://ttm.financial/m/news/2256409604?lang=&edition=fundamental","pubTime":"2022-08-03 09:17","market":"us","language":"en","title":"Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2256409604","media":"InvestorPlace","summary":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON","content":"<html><head></head><body><ul><li>Cannabis stocks are on the move today, including <b>Tilray</b> (<b><u>TLRY</u></b>), <b>Canopy Growth</b> (<b><u>CGC</u></b>) and <b>Cronos</b> (<b><u>CRON</u></b>), among others.</li><li>Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.</li><li>Growing international legalization momentum also fundamentally support cannabis stocks.<img src=\"https://static.tigerbbs.com/54622a5e690d654992a438adc0feb663\" tg-width=\"768\" tg-height=\"432\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></li></ul><p>Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players <b>Tilray</b> (NASDAQ:<b><u>TLRY</u></b>), <b>Canopy Growth</b> (NASDAQ:<b><u>CGC</u></b>) and <b>Cronos</b> (NASDAQ:<b><u>CRON</u></b>) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.</p><p>On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.</p><p>In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.</p><p>On the international front, cannabis stocks may be responding to a <i>Forbes</i> article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.</p><p>Interestingly, Tilray tweeted a link to the <i>Forbes</i> article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.</p><h2>Cannabis Stocks Still Have a Challenging Road Ahead</h2><p>Jefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.</p><p>This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.</p><p>A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.</p><p>Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.</p><p>Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”</p><p>In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.</p><h2>Why It Matters</h2><p>Although beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Cannabis Stocks TLRY, CGC, CRON Up Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-03 09:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough...</p>\n\n<a href=\"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","CGC":"Canopy Growth Corporation","BK4557":"大麻股","TLRY":"Tilray Inc.","BK4547":"WSB热门概念","CRON":"Cronos Group Inc."},"source_url":"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2256409604","content_text":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.Growing international legalization momentum also fundamentally support cannabis stocks.Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players Tilray (NASDAQ:TLRY), Canopy Growth (NASDAQ:CGC) and Cronos (NASDAQ:CRON) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.On the international front, cannabis stocks may be responding to a Forbes article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.Interestingly, Tilray tweeted a link to the Forbes article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.Cannabis Stocks Still Have a Challenging Road AheadJefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.Why It MattersAlthough beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9906370511,"gmtCreate":1659490619235,"gmtModify":1705980925366,"author":{"id":"3575125836760247","authorId":"3575125836760247","name":"Singman","avatar":"https://static.tigerbbs.com/d770feb757705f2d631d2d5f381ae07b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575125836760247","authorIdStr":"3575125836760247"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9906370511","repostId":2256409604,"repostType":4,"repost":{"id":"2256409604","kind":"highlight","pubTimestamp":1659489465,"share":"https://ttm.financial/m/news/2256409604?lang=&edition=fundamental","pubTime":"2022-08-03 09:17","market":"us","language":"en","title":"Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2256409604","media":"InvestorPlace","summary":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON","content":"<html><head></head><body><ul><li>Cannabis stocks are on the move today, including <b>Tilray</b> (<b><u>TLRY</u></b>), <b>Canopy Growth</b> (<b><u>CGC</u></b>) and <b>Cronos</b> (<b><u>CRON</u></b>), among others.</li><li>Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.</li><li>Growing international legalization momentum also fundamentally support cannabis stocks.<img src=\"https://static.tigerbbs.com/54622a5e690d654992a438adc0feb663\" tg-width=\"768\" tg-height=\"432\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></li></ul><p>Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players <b>Tilray</b> (NASDAQ:<b><u>TLRY</u></b>), <b>Canopy Growth</b> (NASDAQ:<b><u>CGC</u></b>) and <b>Cronos</b> (NASDAQ:<b><u>CRON</u></b>) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.</p><p>On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.</p><p>In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.</p><p>On the international front, cannabis stocks may be responding to a <i>Forbes</i> article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.</p><p>Interestingly, Tilray tweeted a link to the <i>Forbes</i> article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.</p><h2>Cannabis Stocks Still Have a Challenging Road Ahead</h2><p>Jefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.</p><p>This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.</p><p>A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.</p><p>Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.</p><p>Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”</p><p>In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.</p><h2>Why It Matters</h2><p>Although beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Cannabis Stocks TLRY, CGC, CRON Up Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-03 09:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough...</p>\n\n<a href=\"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","CGC":"Canopy Growth Corporation","BK4557":"大麻股","TLRY":"Tilray Inc.","BK4547":"WSB热门概念","CRON":"Cronos Group Inc."},"source_url":"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2256409604","content_text":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.Growing international legalization momentum also fundamentally support cannabis stocks.Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players Tilray (NASDAQ:TLRY), Canopy Growth (NASDAQ:CGC) and Cronos (NASDAQ:CRON) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.On the international front, cannabis stocks may be responding to a Forbes article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.Interestingly, Tilray tweeted a link to the Forbes article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.Cannabis Stocks Still Have a Challenging Road AheadJefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.Why It MattersAlthough beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9906347361,"gmtCreate":1659490525856,"gmtModify":1705980922920,"author":{"id":"4101534862379370","authorId":"4101534862379370","name":"potato112","avatar":"https://static.itradeup.com/news/c979f6cdb3624170ce5e74ecfed3c464","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"4101534862379370","authorIdStr":"4101534862379370"},"htmlText":"Like pls. Tq!","listText":"Like pls. Tq!","text":"Like pls. Tq!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/9906347361","repostId":2256409604,"repostType":4,"repost":{"id":"2256409604","kind":"highlight","pubTimestamp":1659489465,"share":"https://ttm.financial/m/news/2256409604?lang=&edition=fundamental","pubTime":"2022-08-03 09:17","market":"us","language":"en","title":"Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2256409604","media":"InvestorPlace","summary":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON","content":"<html><head></head><body><ul><li>Cannabis stocks are on the move today, including <b>Tilray</b> (<b><u>TLRY</u></b>), <b>Canopy Growth</b> (<b><u>CGC</u></b>) and <b>Cronos</b> (<b><u>CRON</u></b>), among others.</li><li>Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.</li><li>Growing international legalization momentum also fundamentally support cannabis stocks.<img src=\"https://static.tigerbbs.com/54622a5e690d654992a438adc0feb663\" tg-width=\"768\" tg-height=\"432\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></li></ul><p>Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players <b>Tilray</b> (NASDAQ:<b><u>TLRY</u></b>), <b>Canopy Growth</b> (NASDAQ:<b><u>CGC</u></b>) and <b>Cronos</b> (NASDAQ:<b><u>CRON</u></b>) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.</p><p>On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.</p><p>In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.</p><p>On the international front, cannabis stocks may be responding to a <i>Forbes</i> article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.</p><p>Interestingly, Tilray tweeted a link to the <i>Forbes</i> article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.</p><h2>Cannabis Stocks Still Have a Challenging Road Ahead</h2><p>Jefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.</p><p>This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.</p><p>A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.</p><p>Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.</p><p>Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”</p><p>In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.</p><h2>Why It Matters</h2><p>Although beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Cannabis Stocks TLRY, CGC, CRON Up Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Cannabis Stocks TLRY, CGC, CRON Up Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-03 09:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough...</p>\n\n<a href=\"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","CGC":"Canopy Growth Corporation","BK4557":"大麻股","TLRY":"Tilray Inc.","BK4547":"WSB热门概念","CRON":"Cronos Group Inc."},"source_url":"https://investorplace.com/2022/08/why-are-cannabis-stocks-tlry-cgc-cron-up-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2256409604","content_text":"Cannabis stocks are on the move today, including Tilray (TLRY), Canopy Growth (CGC) and Cronos (CRON), among others.Tilray delivered some encouraging news for its fiscal year 2022 results amid a rough outing for the industry.Growing international legalization momentum also fundamentally support cannabis stocks.Following a rough first half of the year, cannabis stocks are finally enjoying some positive momentum. Key players Tilray (NASDAQ:TLRY), Canopy Growth (NASDAQ:CGC) and Cronos (NASDAQ:CRON) are finally gaining significant ground. Though the news cycle for the botanical sector was light, Tilray last week released its financial results for its fiscal year 2022, featuring some positive dynamics. Combined with legalization news from Switzerland, the industry may be rising in sympathy.On July 28, Tilray reported that FY 2022 net revenue increased 22% to $628 million compared to the prior year. When adjusted for currency fluctuations, net revenue increased by 29%. Additionally, net sales in the fiscal fourth quarter (ended May 31, 2022) amounted to $153 million, representing year-over-year growth of 8%. On a constant currency basis, Q4 sales increased by 14% to $163 million.In addition, management disclosed that it expects to generate $70 million to $80 million of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). As well, it anticipates to be free cash flow positive in its operating business units in FY 2023. Thus, the leadership team believes it has a foundation set for profitable and sustainable growth.On the international front, cannabis stocks may be responding to a Forbes article, which reported that Switzerland has now fully legalized medical cannabis and allows for exporting the historically maligned plant. Notably, from Aug. 1, Swiss patients can get medical cannabis through a prescription.Interestingly, Tilray tweeted a link to the Forbes article, presumably because the company specializes in medicinal cannabis. In 2018, Tilray inked a research deal with the University of California School of Medicine.Cannabis Stocks Still Have a Challenging Road AheadJefferies analysts weighed in on Tilray’s results for FY 2022, particularly noting that they see “signs of Canadian improvement” in the disclosure. Despite this glimmer of hope, Jefferies trimmed its price target by 23%, aiming now for a $9.30 per share. To be fair, the analysts reaffirmed their “buy” rating for TLRY stock.This somewhat mixed messaging generally reflects the overriding mood for cannabis stocks. Though the increase in Tilray’s revenue combined with the Switzerland news are encouraging news items, it’s important to note that this “green” sector remains embattled. For instance, while TLRY stock is up 14% in the afternoon session, on a year-to-date (YTD) basis, it’s down 47%.A similar narrative haunts Canopy Growth and Cronos. Although both firms are enjoying a resurgent swing this afternoon, they’re down 69% YTD and 21% YTD, respectively.Moreover, investors should recognize that not every item within Tilray’s FY 2022 report was heartening. Specifically, net loss in fiscal Q4 was $457.8 million, comparing very unfavorably to net income of $33.6 million in the year-ago quarter. The aforementioned net loss included a non-cash impairment of $395 million.Management stated on its disclosure that the “impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.”In other words, the Federal Reserve’s policy of attacking the soaring inflation rate through higher interest rates is affecting Tilray to some degree, posing concerns for cannabis stocks broadly.Why It MattersAlthough beleaguered stakeholders of cannabis stocks will take whatever positive catalyst roll their way, they also face stern risks from the black market. As higher borrowing costs weigh down the market — as Tilray’s FY 2022 disclosure admitted — the temptation for consumers to seek illicit (and therefore cheaper) botanical products will likely rise. Therefore, cannabis investors are still not out of the woods.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":103835312,"gmtCreate":1662683171059,"gmtModify":1663258500238,"authorId":4101534862379370,"author":{"id":4101534862379370,"idStr":"4101534862379370","authorId":4101534862379370,"name":"potato112","avatar":"https://static.itradeup.com/news/c979f6cdb3624170ce5e74ecfed3c464","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.07","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9906347361,"type":1,"supId":103244239,"prevId":0,"content":"comment back haha","text":"comment back haha","html":"comment back haha"},{"id":103244239,"gmtCreate":1659649245438,"gmtModify":1663255570750,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"currentWearingBadge":{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1102},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9906347361,"type":1,"supId":0,"prevId":0,"content":"hi, please like and comment back. thank you.","text":"hi, please like and comment back. thank you.","html":"hi, please like and comment back. thank you."},{"id":103214625,"gmtCreate":1659493312281,"gmtModify":1663255444925,"authorId":4109504542406510,"author":{"id":4109504542406510,"idStr":"4109504542406510","authorId":4109504542406510,"name":"Pepermintpat","avatar":"https://community-static.tradeup.com/news/0804feddbf156f8e808003b7ca831628","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.29","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":3,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9906347361,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">LIke</span>","text":"<span class=\"s1\">LIke</span>","html":"<span class=\"s1\">LIke</span>"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":140,"commentSize":11,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}